Abstracts tagged "Minority Health"

Abstract Number: 0179 • ACR Convergence 2024
Bridging the Gap: Enhancing Diversity in Lupus Clinical Trials Through Investigator and Research Staff Engagement
Tessa Englund¹, Katherine Holben¹, Simone Frank², Khadeejatul-Kubraa Lawal¹, Julie Hsieh³, Christine Lee³ and Saira Sheikh¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³U.S. Food and Drug Administration, Silver Spring, MD
Background/Purpose: Lupus disproportionately affects diverse racial and ethnic minority populations, yet there is a significant disparity between those affected and those enrolled in clinical trials.…
Abstract Number: 0180 • ACR Convergence 2024
Collaborative Solutions to Lupus Trial Challenges for Underrepresented Participant Recruitment & Engagement: Perspectives from the Lupus Clinical Investigators Network (LuCIN)
Brandon Jackson¹, Maria Dall'Era², Saira Sheikh³, Xueting Zhang⁴, Taylor Irons⁵, Claire Finney⁶, Taylor Adjei⁷, Jennifer Meriwether⁷, Caroline Donovan⁸, Carla Menezes⁹ and Stacie Bell¹⁰, ¹Lupus Research Alliance / Lupus Therapeutics, Miami, FL, ²UCSF, Corte Madera, CA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Weill Cornell, New York, NY, ⁵Lupus Research Alliance / Lupus Therapeutics, Houston, ⁶Lupus Research Alliance / Lupus Therapeutics, Birmingham, AL, ⁷Lupus Research Alliance / Lupus Therapeutics, New York, NY, ⁸Lupus Research Alliance / Lupus Therapeutics, Arlington, VA, ⁹Lupus Research Alliance / Lupus Therapeutics, Brooklyn, NY, ¹⁰Lupus Therapeutics, Lakewood, CO
Background/Purpose: Racial and ethnic minority groups face higher lupus prevalence and severity and remain inadequately represented in lupus clinical trials. Lupus Therapeutics, the clinical affiliate…
Abstract Number: 0193 • ACR Convergence 2024
New York City Lupus Clinical Trials Education Program
Maya Souvignier¹, Leila Khalili¹, Wai Yan April Fu², Laura Geraldino³, Nancyanne Schmidt¹, Yevgeniya Gartshteyn⁴, Peter Izmirly⁵, Noa Schwartz⁶ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Albert Einstein College of Medicine, New York, NY, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Columbia University Irving School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Clinical trial (CT) participation is essential for the advancement of treatment paradigms and should be considered part of clinical care in SLE. CTs fail…
Abstract Number: 1015 • ACR Convergence 2024
Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Viet Bui¹, Miguel Rodriguez² and Sarah Ormseth³, ¹Harbor UCLA Medical Center and The Lundquist Institute, Torrance, CA, ²Texas Arthritis Center, El Paso, TX, ³The Lundquist Institute, Torrance, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 1019 • ACR Convergence 2024
The Impact of Race and Ethnicity and Historical Redlining on Psoriatic Disease Burden
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Previous literature has suggested racial and ethnic variations in the clinical expression of psoriatic disease, with Non-White patients having more extensive skin disease, higher…
Abstract Number: 1023 • ACR Convergence 2024
Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors
Igor Dombrovsky¹, Michael George², Joshua Baker² and Thomas Riley³, ¹Pennsylvania Hospital, Philadephia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Hopsital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Access to Janus kinase inhibitors (JAKi) is controlled by insurance carriers through prior authorizations and the use of restricted formularies. We previously showed that…
Abstract Number: 1230 • ACR Convergence 2024
Mediating Role of Pain Catastrophizing in Racial Disparities in Knee Osteoarthritis Pain Among Non-Hispanic White and Asian Americans: A Pilot Study
Chiyoung Lee¹, Kent Kwoh² and Hyochol Ahn¹, ¹University of Arizona College of Nursing, Tucson, AZ, ²University of Arizona, Tucson, AZ
Background/Purpose: The prevalence of symptomatic knee osteoarthritis (OA) is projected to increase among racially and ethnically marginalized groups. Although recent studies have begun to delineate…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
Abstract Number: 1761 • ACR Convergence 2024
Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry
Sabrina George¹, Hannah C Ainsworth², Kaiyu Jiang³, Gilad Barshad⁴, Adam He⁴, Edward Rice⁴, Carl D Langerfeld², Charles G Danko⁴ and James N Jarvis³, ¹University at Buffalo Jacobs School of Medicine, Buffalo, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Cornell University Baker School of Veterinary Medicine, Ithaca, NY
Background/Purpose: - Numerous juvenile idiopathic arthritis (JIA) risk loci have been identified, overwhelmingly from cohorts of children of European ancestry (EA). The extent to which…
Abstract Number: 1505 • ACR Convergence 2023
Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies
Gabriel Contreras¹, Matt Baker², Lucy Hodge² and Ernie Yap², ¹University of Miami Health System, Miami, FL, ²Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada
Background/Purpose: Black patients with lupus nephritis (LN) are reported to have more severe disease, are often refractory to treatment, and have worse long-term outcomes. Voclosporin…
Abstract Number: 1695 • ACR Convergence 2023
Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis
Philip Carlucci¹, Jasmine Shwetar², Siddarth Gurajala³, Qian Xiao³, Joseph Mears⁴, Katie Preisinger¹, Devyn Zaminski⁵, Kristina Deonaraine¹, Peter Izmirly¹, Andrea Fava⁶, Judith James⁷, Joel Guthridge⁷, Brad Rovin⁸, Sethu Madhavan⁸, Wade DeJager⁷, David Wofsy⁹, Ming Wu², Chaim Putterman¹⁰, Deepak Rao¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont⁵, William Apruzzese¹¹, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹¹, Celine Berthier¹⁷, Maria Dall'Era⁹, Kerry Cho¹⁸, Diane L. Kamen¹⁹, Kenneth Kalunian²⁰, Jennifer Anolik²¹, Arnon Arazi²², Soumya Raychaudhuri¹¹, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, Kelly Ruggles², Jill Buyon²⁵ and The Accelerating Medicines Partnership in RA/SLE²⁶, ¹New York University School of Medicine, New York, NY, ²NYU Langone, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Ohio State University, Columbus, OH, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Albert Einstein College of Medicine, Bronx, NY, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸UCSF Health, San Francisco, CA, ¹⁹Medical University of South Carolina, Charleston, SC, ²⁰University of California San Diego, La Jolla, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Broad Institute of MIT and Harvard, Melrose, MA, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Multiple, Bethesda, MD
Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
Abstract Number: 2087 • ACR Convergence 2023
Racial and Ethnic Diversity in Pediatric Fellowships: Fortifying the Pipeline
Bessie Roca Loor¹, Maya Pandit², Tracey Wright³ and Mill Etienne⁴, ¹New York Medical College, Yonkers, NY, ²Columbia University, New York, NY, ³UT Southwestern, Dallas, TX, ⁴New York Medical College, Valhalla, NY
Background/Purpose: The 2015 American College of Rheumatology Workforce study estimated the pediatric rheumatology full-time equivalent workforce to be 300 providers while the estimated excess demand…
Abstract Number: 2088 • ACR Convergence 2023
Room for Racial and Ethnic Diversity in Adult Rheumatology Fellowship Pipeline
Bessie Roca Loor¹, Maya Pandit², Tracey Wright³ and Mill Etienne⁴, ¹New York Medical College, Yonkers, NY, ²Columbia University, New York, NY, ³UT Southwestern, Dallas, TX, ⁴New York Medical College, Valhalla, NY
Background/Purpose: The 2015 American College of Rheumatology Workforce study showed 8 of 1011 adult rheumatologists identified as Black, 85 Hispanic and 3 American Indian or…
Abstract Number: 2092 • ACR Convergence 2023
Feasibility and Efficacy of Culturally Appropriate Spanish Language-First Patient Education for Rheumatoid Arthritis
Daniel Hernandez¹, Julio Bravo², Juan Maya Villamizar³, Oscar Soto⁴, Angel Tapia⁵, Guillermo Valenzuela⁶, W. Benjamin Nowell⁷ and Shilpa Venkatachalam⁸, ¹Global Healthy Living Foundation, St. Johns, FL, ²Novant, Winston-Salem, NC, ³Rheumatology Center of Palm Beach, PLLC, Boca Raton, FL, ⁴Mindful Rheumatix and Medical Research Group, San Juan, PR, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Global Healthy Living Foundation, Nyack, NY, ⁸Global Healthy Living Foundation, New York, NY
Background/Purpose: Spanish-speaking patients with rheumatic arthritis (RA) need RA education that is medically accurate, conversational, and engaging. Our study examined the feasibility and efficacy of…
Abstract Number: 2456 • ACR Convergence 2023
Lupus Patient Navigator Program to Improve Healthcare Barriers for Minority Patients
Samiha Karim¹, Gary Link¹, Dulaney Wilson¹, Jim Oates¹, Gary Gilkeson¹, Jasvinder Singh² and Diane L. Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Despite recent progress in diagnosis and treatment of SLE minorities continue to bear the greater burden of disease with disproportionately higher morbidity and mortality.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].